In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before the publication of the complete year-end report.
Summary of Q4 2024:
- Devyser's net sales increased to MSEK 64.2 (45.4), corresponding to an organic net sales growth of 41.5 percent.
- Gross margin amounted to 84.4 percent (88.1).
- EBIT amounted to MSEK 0.7 (-18.5).
No further information will be provided until Devyser publishes the year-end report for 2024 on February 13 at 10:00 CET. The invitation to the conference call will be announced separately.
Note that the summary of the fourth quarter of 2024 has not been reviewed by the company's auditors.
For more information, please contact
Mia Arnhult, Chairman of the Board of Directors, tel. +46 70-769 82 46
Fredrik Dahl, acting CEO, tel. +46 73-091 74 40
About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.
Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.
For more information, visit www.devyser.com.
This information is information that Devyser Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-01-16 11:15 CET.
